These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32304764)

  • 21. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
    Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
    Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
    Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential.
    Zhang J; Zhang Z; Ma C; Zeng L; Zhang Y; Wang P; Xu L
    Life Sci; 2020 Sep; 256():117853. PubMed ID: 32470452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
    Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling oxyntomodulin, GLP1's enigmatic brother.
    Pocai A
    J Endocrinol; 2012 Dec; 215(3):335-46. PubMed ID: 23019069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
    Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
    Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2010 Dec; 80(11):1727-35. PubMed ID: 20735990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
    Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
    Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor.
    Sowden GL; Drucker DJ; Weinshenker D; Swoap SJ
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R962-70. PubMed ID: 17038440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
    Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
    J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
    Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
    Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
    Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
    Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
    Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
    Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y
    Yuan Y; Yan Z; Lao Q; Jiang N; Wu S; Lu Q; Han J; Zhao S
    Eur J Med Chem; 2023 Feb; 247():115036. PubMed ID: 36571995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
    Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
    J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
    Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
    Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DPP-IV-resistant, long-acting oxyntomodulin derivatives.
    Santoprete A; Capitò E; Carrington PE; Pocai A; Finotto M; Langella A; Ingallinella P; Zytko K; Bufali S; Cianetti S; Veneziano M; Bonelli F; Zhu L; Monteagudo E; Marsh DJ; Sinharoy R; Bianchi E; Pessi A
    J Pept Sci; 2011 Apr; 17(4):270-80. PubMed ID: 21294225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.